Properties
- Form
- sirofi
- Dosage mg
- 30მგ/5
- Pack
- 1
What is it?
LAZOLVAN Clinical-pharmacological group: Mucolytic, expectorant. Composition and dosage form: Syrup: in a 100 ml bottle 5 ml Ambroxol hydrochloride ..........15 mg 5 ml Ambroxol hydrochloride ..........30 mg Pharmacological properties: Ambroxol hydrochloride is an active metabolite of bromhexine from the benzilamine group, characterized by mucolytic and expectorant action. The preparation stimulates the secretion of mucus by the adenocytes of the bronchial mucosa, thereby promoting sputum thinning. It activates hydrolytic enzymes and enhances the release of lysosomes from Clara cells, leading to the breakdown of acid mucopolysaccharides in bronchial secretions. Lysyl action enhances the process of surfactant formation in the alveoli and bronchi, which also improves the rheological parameters of bronchial secretions, reducing its viscosity and adhesive properties. By stimulating surfactant synthesis, the preparation reduces the risk of developing respiratory distress syndrome in newborns (including premature infants). Lysyl stimulates the ciliary movement of the bronchial epithelium, which promotes sputum evacuation and reduces bronchial spastic hyperreactivity. The preparation has anti-inflammatory and antioxidant effects, and increases local immunity. The action of the preparation begins 30 minutes after administration and lasts for 6-12 hours (depending on the dose). The maximum therapeutic effect is observed on the third day of treatment. Pharmacokinetics: LAZOLVAN is rapidly and almost completely absorbed from the gastrointestinal tract. It reaches maximum plasma concentration within 0.5-3 hours. The bioavailability of the preparation is approximately 70%. It is 80% bound to plasma proteins. Due to high tropism, the preparation is easily distributed to the bronchial mucosa and lung tissue. Ambroxol crosses the blood-brain and placental barriers; its concentration in fetal plasma is 2-4 times higher than in maternal plasma. The preparation passes into breast milk. The half-life of ambroxol is 8-10 hours. T1/2 is prolonged in severe chronic renal failure and does not change in liver dysfunction. The preparation undergoes initial metabolism in the liver, forming inactive conjugates (dibromantranilic acid, glucuronides). It is excreted from the body by the kidneys: 90% as water-soluble metabolites, 5% unchanged. Ambroxol does not accumulate. Indications: Acute and chronic diseases of the respiratory system accompanied by difficult sputum expectoration: bronchitis, bronchiolitis, bronchial asthma, pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis; prophylaxis of stagnant diseases in the bronchi and lungs (after surgical operations, during trauma, etc.). Dosage and administration: Tablets: For adults and children over 12 years of age, during the first 2-3 days of treatment, 1 tablet (30 mg) 3 times a day is recommended, then 1 tablet 2 times a day or 1/2 tablet (15 mg) 3 times a day. If necessary, to enhance the therapeutic effect, 2 tablets (60 mg) twice a day can be prescribed. For children aged 5 to 12 years, 1/2 tablet 2-3 times a day is prescribed. Syrup: For adults and children over 12 years of age, during the first 2-3 days of treatment, 10 ml 3 times a day is recommended, then 10 ml 2 times a day or 5 ml 3 times a day. For adults, 20 ml twice a day can be taken to achieve a therapeutic effect. For children aged 5 to 12 years, 5 ml 2-3 times a day is recommended. For children aged 2 to 5 years, 2.5 ml 3 times a day is recommended. For children under 2 years of age, 2.5 ml twice a day is prescribed. LAZOLVAN (tablets or syrup) should be taken after meals with a large amount of fluid, which helps to enhance the mucolytic effect of the preparation. In case of acute renal failure or severe liver dysfunction, the dose of the preparation should be reduced or the interval between doses increased. The duration of treatment is determined individually by the doctor and depends on the severity of the illness. Prolonged use of the preparation requires medical supervision. If the course of treatment is prolonged, the dose can be reduced by half. Violation of the dosage regimen reduces the effectiveness of treatment. Side effects: Side effects are not observed when the preparation is taken at recommended doses. Rarely, the following may occur: Gastrointestinal system: dyspeptic events; Respiratory system: dryness of the bronchial mucosa, rhinorrhea; Allergic reactions: skin rash, itching, urticaria, angioedema; in isolated cases - allergic contact dermatitis; in single cases - anaphylactic reactions (including anaphylactic shock); Other: general weakness, headache, dysuria. Contraindications: * Hypersensitivity to any component of the preparation or to bromhexine. Pregnancy and lactation: * LAZOLVAN is not recommended for use during the first trimester of pregnancy. * The preparation can be taken during the second and third trimesters of pregnancy only when the expected benefit to the mother significantly outweighs the potential risk of adverse effects on the fetus. * The preparation passes into breast milk, therefore, breastfeeding should be discontinued during treatment. Special instructions: * LAZOLVAN should be used with caution in case of impaired renal function and/or severe liver damage, and in motor bronchopathy, as delayed sputum evacuation is possible. * The syrup contains sugar substitutes such as sorbitol and saccharin, so it can be taken by patients with diabetes mellitus, taking into account that every 5 ml of syrup contains 1.2 g of sorbitol. The syrup does not contain ethanol. * The preparation may affect the clinical picture of gastric and duodenal ulcer disease. The patient should be informed that if the condition worsens or side effects develop, they should consult a doctor. Effect on ability to drive and operate machinery: The preparation does not affect the ability to drive vehicles and concentrate attention. Overdose: In case of overdose, the following symptoms may occur: nausea, vomiting, diarrhea and other gastrointestinal disorders. In case of severe overdose, sharp arterial hypotension is possible. Treatment: Discontinuation of the preparation, induction of vomiting, gastric lavage (only in case of extreme overdose) within 1-2 hours after administration, intake of fluids (milk, tea), fatty foods, continuous monitoring of cardiovascular function, and symptomatic treatment if necessary. Interaction with other drugs: - LAZOLVAN promotes the penetration of antimicrobial agents (amoxicillin, cefuroxime, erythromycin, doxycycline, sulfanilamides) into the bronchial mucosa and bronchial secretions. - When ambroxol is used together with theophylline, its concentration in blood plasma increases, which allows for a reduction in the duration of treatment. There is no data on the interaction of ambroxol with other agents used in the basic therapy of bronchial asthma (bronchodilators, methylxanthine derivatives, corticosteroids). - It is not recommended to prescribe the preparation together with antitussives (including codeine), as weakening of the cough hinders sputum expectoration. - The preparation can be used together with cardiac glycosides, diuretics, and tocolytic agents. Storage conditions: Store the preparation at a temperature not exceeding 25°C, in a dry, protected from light and children place. Do not freeze the syrup. After opening the bottle, the syrup is suitable for use for 30 days.
